For mine, this result - especially the combination of soft top line growth (if one strips out Revenue contributions from acquisitions) and pressure on GP Margins - goes a long way to explaining some of the strategic motivations behind the Brightree acquisition earlier this year.
Anyone who had reservations earlier this year, about management's rational for buying Brightree, will have increasing grounds for having those reservations reinforced, I believe.
ResMed's profit down despite revenue rise, page-10
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$37.28 |
Change
0.200(0.54%) |
Mkt cap ! $22.38B | |||
| Open | High | Low | Value | Volume |
| $37.50 | $37.55 | $37.15 | $17.93M | 480.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3363 | $37.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $37.30 | 1001 | 2 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| RMD (ASX) Chart |
